Financement

Financeur: International Association for the Study of Lung Cancer (IASLC)

1 financements - 42 500€

données disponibles depuis 2020

2020

Dual Serine/ Threonine and Tyrosine kinase (DSTYK) as a new target for lung cancer therapy and immunotherapy combination
42 500,00